• 1
    Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 23445.
  • 2
    Nuenninghoff TJ, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complications (aortic aneurysm, aortic dissection, and/or large artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48: 352231.
  • 3
    Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P, Paredes P, Segarra M, Lozano E, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008; 59: 42230.
  • 4
    Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, Pego-Reigosa R, Lopez-Diaz MJ, Vazquez-Trinanes MC, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009; 88: 22735.
  • 5
    Cid MC, Campo E, Ercilla G, Palacin A, Vilaseca J, Villalta J, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis: influence of corticosteroid treatment. Arthritis Rheum 1989; 32: 88493.
  • 6
    Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant-cell arteritis. Ann Intern Med 1994; 121: 48491.
  • 7
    Martinez-Taboada VM, Alvarez L, Ruiz Soto M, Marin-Vidalled MJ, Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008; 44: 20720.
  • 8
    Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43: 294301.
  • 9
    Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107: 242834.
  • 10
    Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, Filella X, Esteban MJ, Lopez-Soto A, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant cell arteritis. Arthritis Rheum 2002; 47: 2935.
  • 11
    Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, Lopez-Soto A, et al. Association between strong systemic inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 2632.
  • 12
    Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant-cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005; 84: 26976.
  • 13
    Cid MC, Garcia-Martinez A, Lozano E, Espigol-Frigole G, Hernandez-Rodriguez J. Five clinical conundrums in the management of giant cell arteritis. Rheum Dis Clin North Am 2007; 33: 81934.
  • 14
    Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 7038.
  • 15
    Hayreth SS, Zimmerman B. Visual deterioration in giant-cell arteritis patients while on high doses of glucocorticosteroid therapy. Ophthalmology 2003; 110: 120415.
  • 16
    Cid MC, Prieto-Gonzalez S, Arguis P, Espigol-Frigole G, Butjosa M, Hernandez-Rodriguez J, et al. The spectrum of vascular involvement in giant-cell arteritis: clinical consequences of detrimental vascular remodelling at different sites. APMIS Suppl 2009; 127: 1020.
  • 17
    Park JL, Jones JG, Hazleman BL. Relationship of the ESR to acute phase proteins in polymyalgia rheumatica and giant-cell arteritis. Ann Rheum Dis 1981; 40: 4935.
  • 18
    Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36: 128694.
  • 19
    Cid MC, Monteagudo J, Oristrell J, Vilaseca J, Pallares L, Cervera R, et al. Von Willebrand factor in the outcome of temporal arteritis. Ann Rheum Dis 1996; 55: 92730.
  • 20
    Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 10418.
  • 21
    Fauchald P, Ryqvold O, Oytese B. Temporal arteritis and polymyalgia rheumatica. Ann Intern Med 1972; 77: 84552.
  • 22
    Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995; 122: 5027.
  • 23
    Lozano E, Segarra M, Garcia-Martinez A, Hernandez-Rodriguez J, Cid MC. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant-cell arteritis. Ann Rheum Dis 2008; 67: 15818.
  • 24
    Lozano E, Corbera-Bellalta M, Espigol-Frigole G, Garcia-Martinez A, Hernandez-Rodriguez J, Cid MC, et al. Proinflammatory functions of vascular smooth muscle cells (VSMC) in giant cell arteritis (GCA) [abstract]. Arthritis Rheum 2008; 58 Suppl: S9289.
  • 25
    Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, et al. Relationship between interleukin-6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 2006; 33: 7038.
  • 26
    Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997; 94: 31959.
  • 27
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399406.
  • 28
    Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144: 24956.
  • 29
    Van Leuven SI, Kastelein JJ, D'Cruz DP, Hughes GR, Stroes ES. Atherogenesis in rheumatology. Lupus 2006; 15: 11721.
  • 30
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, et al. HLA–DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 12532.
  • 31
    Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh artery study. Circulation 2005; 112: 97683.
  • 32
    Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parenteral history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 25: 224351.
  • 33
    Gonzalez-Juanatey C, Lopez-Diaz MJ, Martin J, Llorca J, Gonzalez-Gay MA. Atherosclerosis in patients with biopsy-proven giant cell arteritis. Arthritis Rheum 2007; 57: 14816.
  • 34
    Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005; 53: 338.
  • 35
    Nesher G, Nesher R, Mates M, Sonnenblick M, Breuer GS. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol 2008; 26 Suppl: S304.
  • 36
    Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al, for the Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 2007; 146: 62130.
  • 37
    Lozano E, Segarra M, Garcia-Martinez A, Espigol-Frigole G, Hernandez-Rodriguez J, Cid MC, et al. New therapeutic targets in giant-cell arteritis: considerations based on the current pathogenic model and the availability of new therapeutic targets. Clin Exp Rheumatol 2008; 26 Suppl: S14150.
  • 38
    Queralt C, Hernandez-Rodriguez J, Garcia-Martinez A, Esteban MJ, Ros I, Fernandez J, et al. Baseline osteopenia is associated with subsequent bone loss and fractures in glucocorticosteroid-treated patients with giant-cell arteritis (GCA) receiving calcium and vitamin D supplements [abstract]. Arthritis Rheum 2000; 43 Suppl: S1793.
  • 39
    Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al. Glucocorticosteroid-induced diabetes mellitus: prevalence and risk factors in primary renal disease. Nephron Clin Pract 2007; 105: C547.
  • 40
    Hellmann DB, Uhlfelder ML, Stone JH, Jenckes MW, Cid MC, Guillevin L, et al. Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis Rheum 2003; 49: 81925.